JP2007531759A - 特定の脱フィブリノーゲンパターンを達成するために脱フィブリノーゲン剤投与を用いる脳卒中の治療方法 - Google Patents
特定の脱フィブリノーゲンパターンを達成するために脱フィブリノーゲン剤投与を用いる脳卒中の治療方法 Download PDFInfo
- Publication number
- JP2007531759A JP2007531759A JP2007506521A JP2007506521A JP2007531759A JP 2007531759 A JP2007531759 A JP 2007531759A JP 2007506521 A JP2007506521 A JP 2007506521A JP 2007506521 A JP2007506521 A JP 2007506521A JP 2007531759 A JP2007531759 A JP 2007531759A
- Authority
- JP
- Japan
- Prior art keywords
- defibrinogen
- ancrod
- treatment
- stroke
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 70
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 69
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 69
- 108010001779 Ancrod Proteins 0.000 claims description 103
- 229960004233 ancrod Drugs 0.000 claims description 90
- 238000010606 normalization Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 25
- 206010018985 Haemorrhage intracranial Diseases 0.000 abstract description 24
- 208000008574 Intracranial Hemorrhages Diseases 0.000 abstract description 24
- 208000032382 Ischaemic stroke Diseases 0.000 abstract description 20
- 206010051125 Hypofibrinogenaemia Diseases 0.000 abstract description 10
- 230000007774 longterm Effects 0.000 abstract description 7
- 208000006011 Stroke Diseases 0.000 description 44
- 239000000902 placebo Substances 0.000 description 34
- 229940068196 placebo Drugs 0.000 description 34
- 238000001802 infusion Methods 0.000 description 25
- 238000002203 pretreatment Methods 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 11
- 238000001990 intravenous administration Methods 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229960004072 thrombin Drugs 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002435 venom Substances 0.000 description 4
- 210000001048 venom Anatomy 0.000 description 4
- 231100000611 venom Toxicity 0.000 description 4
- 108010071289 Factor XIII Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 241000254173 Coleoptera Species 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 101800000974 Fibrinopeptide A Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 238000012950 reanalysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 241000271039 Agkistrodon Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000271064 Calloselasma rhodostoma Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- 101800003778 Fibrinopeptide B Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001114088 Rhodosoma Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003536 defibrinogenating effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000010336 energy treatment Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 230000001471 fibrinogenolytic effect Effects 0.000 description 1
- 239000002350 fibrinopeptide Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000002345 thrombinlike Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/812,510 US20050220782A1 (en) | 2004-03-30 | 2004-03-30 | Method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern |
| PCT/US2005/010769 WO2005097262A1 (en) | 2004-03-30 | 2005-03-30 | A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007531759A true JP2007531759A (ja) | 2007-11-08 |
| JP2007531759A5 JP2007531759A5 (https=) | 2008-05-15 |
Family
ID=34964955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506521A Withdrawn JP2007531759A (ja) | 2004-03-30 | 2005-03-30 | 特定の脱フィブリノーゲンパターンを達成するために脱フィブリノーゲン剤投与を用いる脳卒中の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050220782A1 (https=) |
| EP (1) | EP1740271A1 (https=) |
| JP (1) | JP2007531759A (https=) |
| AU (1) | AU2005231769A1 (https=) |
| CA (1) | CA2561645A1 (https=) |
| IL (1) | IL178426A0 (https=) |
| RU (1) | RU2006138043A (https=) |
| WO (1) | WO2005097262A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102016110642A1 (de) * | 2016-06-09 | 2017-12-14 | Nordmark Holding Gmbh | Verwendung von Ancrod zur Vorbeugung und/oder Behandlung von Ischämie |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523292A (en) * | 1992-10-14 | 1996-06-04 | Schwartz; Robert | Method of preventing restenosis following coronary angioplasty |
| US6165795A (en) * | 1998-06-25 | 2000-12-26 | Cardiovascular Diagnostics, Inc. | Methods for performing fibrinogen assays using dry chemical reagents containing ecarin and magnetic particles |
-
2004
- 2004-03-30 US US10/812,510 patent/US20050220782A1/en not_active Abandoned
-
2005
- 2005-03-30 EP EP05733220A patent/EP1740271A1/en not_active Withdrawn
- 2005-03-30 JP JP2007506521A patent/JP2007531759A/ja not_active Withdrawn
- 2005-03-30 WO PCT/US2005/010769 patent/WO2005097262A1/en not_active Ceased
- 2005-03-30 RU RU2006138043/14A patent/RU2006138043A/ru not_active Application Discontinuation
- 2005-03-30 CA CA002561645A patent/CA2561645A1/en not_active Abandoned
- 2005-03-30 AU AU2005231769A patent/AU2005231769A1/en not_active Abandoned
-
2006
- 2006-10-03 IL IL178426A patent/IL178426A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2561645A1 (en) | 2005-10-20 |
| AU2005231769A1 (en) | 2005-10-20 |
| IL178426A0 (en) | 2007-02-11 |
| RU2006138043A (ru) | 2008-05-10 |
| US20050220782A1 (en) | 2005-10-06 |
| WO2005097262A1 (en) | 2005-10-20 |
| EP1740271A1 (en) | 2007-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goldhaber et al. | Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial | |
| Cohen et al. | Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study | |
| US5180583A (en) | Method for the treatment of bleeding disorders | |
| Magnani | Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction | |
| CN1090029C (zh) | 溶血栓活性蛋白和抗凝血剂的组合物及其应用 | |
| TW200817033A (en) | Method of treating stroke with thrombolytic agent | |
| US20090004177A1 (en) | Combination Treatment with t-PA Variant and Low Molecular Weight Heparin | |
| Siegbahn et al. | Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo | |
| US5690931A (en) | Method for treating thromboembolic conditions via the use of multiple bolus administration of thrombolytically active proteins | |
| Mizuta et al. | Acute Myocardial Infarction in a Patient With Essential Thrombocythemia Successful Treatment With Percutaneous Transluminal Coronary Recanalization | |
| Schulman et al. | Heparin, DDAVP and the bleeding time | |
| JP2007531759A (ja) | 特定の脱フィブリノーゲンパターンを達成するために脱フィブリノーゲン剤投与を用いる脳卒中の治療方法 | |
| RU2216348C1 (ru) | Фармацевтическая композиция, обладающая тромболитическим и фибринолитическим действием | |
| Moon et al. | Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits | |
| Köhler et al. | High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: alterations of the fibrinolytic system and clearance of fibrinolytic activity | |
| US5342616A (en) | Method of administering tissue plasminogen activator | |
| JP2783367B2 (ja) | ヘパリン含有製剤 | |
| Mola et al. | A pilot study of pro-urokinase in the treatment of deep vein thrombosis | |
| EP0352897B1 (en) | Tpa-containing medicaments | |
| US20060135425A1 (en) | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke | |
| JPH0867636A (ja) | 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬 | |
| KR100831770B1 (ko) | ｔ-ＰＡ 변이체와 저분자량 헤파린의 조합 치료 | |
| Deykin | Indications and techniques for the use of heparin in the treatment of thromboembolism | |
| Becker et al. | The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration | |
| CN114984197A (zh) | 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080319 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080319 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090108 |